Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.

Takashita E, Kawakami C, Ogawa R, Morita H, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Ota A, Togashi H, Saito A, Mitamura K, Abe T, Ichikawa M, Yamazaki M, Watanabe S, Odagiri T.

Euro Surveill. 2019 Mar;24(12). doi: 10.2807/1560-7917.ES.2019.24.12.1900170.

2.

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.

Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Mitamura K, Abe T, Ichikawa M, Yamazaki M, Watanabe S, Odagiri T, On Behalf Of The Influenza Virus Surveillance Group Of Japan.

Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800698.

3.

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.

Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T.

Front Microbiol. 2018 Dec 6;9:3026. doi: 10.3389/fmicb.2018.03026. eCollection 2018.

4.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.

Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A.

Antiviral Res. 2018 Sep;157:38-46. doi: 10.1016/j.antiviral.2018.07.001. Epub 2018 Jul 3.

5.

Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.

Kuwahara T, Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Takahashi H, Suzuki N, Kawaoka Y, Watanabe S, Odagiri T.

Jpn J Infect Dis. 2018 May 24;71(3):234-238. doi: 10.7883/yoken.JJID.2017.551. Epub 2018 Apr 27.

6.

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies.

Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y.

Sci Rep. 2017 Dec 18;7(1):17735. doi: 10.1038/s41598-017-17986-8.

7.

A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.

Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Shu Y, Paulson JC, Hasegawa H, Kawaoka Y.

Cell Host Microbe. 2017 Nov 8;22(5):615-626.e8. doi: 10.1016/j.chom.2017.09.008. Epub 2017 Oct 19.

8.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.

Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.

9.

Characterization of influenza A(H1N1)pdm09 viruses isolated from Nepalese and Indian outbreak patients in early 2015.

Nakamura K, Shirakura M, Fujisaki S, Kishida N, Burke DF, Smith DJ, Kuwahara T, Takashita E, Takayama I, Nakauchi M, Chadha M, Potdar V, Bhushan A, Upadhyay BP, Shakya G, Odagiri T, Kageyama T, Watanabe S.

Influenza Other Respir Viruses. 2017 Sep;11(5):399-403. doi: 10.1111/irv.12469. Epub 2017 Aug 9.

10.

TMPRSS2 Independency for Haemagglutinin Cleavage In Vivo Differentiates Influenza B Virus from Influenza A Virus.

Sakai K, Ami Y, Nakajima N, Nakajima K, Kitazawa M, Anraku M, Takayama I, Sangsriratanakul N, Komura M, Sato Y, Asanuma H, Takashita E, Komase K, Takehara K, Tashiro M, Hasegawa H, Odagiri T, Takeda M.

Sci Rep. 2016 Jul 8;6:29430. doi: 10.1038/srep29430.

11.

Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.

Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Kuwahara T, Shimazu Y, Shimomura T, Watanabe S, Odagiri T; Influenza Virus Surveillance Group of Japan.

Euro Surveill. 2016 Jun 16;21(24). doi: 10.2807/1560-7917.ES.2016.21.24.30258.

12.

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.

Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T.

Antiviral Res. 2016 Aug;132:170-7. doi: 10.1016/j.antiviral.2016.06.007. Epub 2016 Jun 16.

13.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.

Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, Meijer A.

Antiviral Res. 2016 Aug;132:178-85. doi: 10.1016/j.antiviral.2016.06.001. Epub 2016 Jun 3. Review.

14.

C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection.

Zhao D, Fukuyama S, Sakai-Tagawa Y, Takashita E, Shoemaker JE, Kawaoka Y.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1902-6. doi: 10.1128/AAC.02055-15.

15.

Characterization of an A (H1N1)pdm09 Virus Imported from India in March 2015.

Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Kuwahara T, Ohmiya S, Sato K, Ito H, Chiba F, Nishimura H, Shindo S, Watanabe S, Odagiri T; Influenza Virus Surveillance Group of Japan.

Jpn J Infect Dis. 2016;69(1):83-6. doi: 10.7883/yoken.JJID.2015.460. Epub 2015 Nov 13. No abstract available.

16.

6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential.

Sriwilaijaroen N, Suzuki K, Takashita E, Hiramatsu H, Kanie O, Suzuki Y.

J Antimicrob Chemother. 2015 Oct;70(10):2797-809. doi: 10.1093/jac/dkv193. Epub 2015 Jul 13.

PMID:
26169554
17.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

18.

Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M.

Antimicrob Agents Chemother. 2015 May;59(5):2607-17. doi: 10.1128/AAC.04836-14. Epub 2015 Feb 17.

19.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.

Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC.

Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17.

20.

A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.

Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, Odagiri T, Tashiro M.

Euro Surveill. 2014 Jan 9;19(1). pii: 20666.

21.

Seroprevalence of a novel influenza A (H3N2) variant virus in the Japanese population.

Kishida N, Imai M, Xu H, Taya K, Fujisaki S, Takashita E, Tashiro M, Odagiri T.

Jpn J Infect Dis. 2013;66(6):549-51.

22.

Characterization of H7N9 influenza A viruses isolated from humans.

Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y.

Nature. 2013 Sep 26;501(7468):551-5. doi: 10.1038/nature12392. Epub 2013 Jul 10.

23.

Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.

Takashita E, Fujisaki S, Kishida N, Xu H, Imai M, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan.

Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8.

24.

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y.

J Virol. 2013 Jul;87(14):7874-81. doi: 10.1128/JVI.00076-13. Epub 2013 May 8.

25.

Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013.

Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M.

Euro Surveill. 2013 Apr 11;18(15):20453. Erratum in: Euro Surveill. 2013;18(16):20459.

26.

Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.

Fujisaki S, Imai M, Takashita E, Taniwaki T, Xu H, Kishida N, Yokoyama M, Sato H, Tashiro M, Odagiri T.

J Infect Chemother. 2013 Oct;19(5):891-5. doi: 10.1007/s10156-013-0589-6. Epub 2013 Mar 26.

PMID:
23529501
27.

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.

Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.

PMID:
23131559
28.

Intrinsic temperature sensitivity of influenza C virus hemagglutinin-esterase-fusion protein.

Takashita E, Muraki Y, Sugawara K, Asao H, Nishimura H, Suzuki K, Tsuji T, Hongo S, Ohara Y, Kawaoka Y, Ozawa M, Matsuzaki Y.

J Virol. 2012 Dec;86(23):13108-11. doi: 10.1128/JVI.01925-12. Epub 2012 Sep 26. Erratum in: J Virol. 2013 Jan;87(2):1288. Ohara, Yoshihiro [corrected to Ohara, Yoshiro].

29.

Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.

Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, Yano T, Suga T, Kawakami C, Yamamoto M, Kajiyama K, Saito H, Shimada S, Watanabe S, Aoki S, Taira K, Kon M, Lin JH, Odagiri T.

Clin Vaccine Immunol. 2012 Jun;19(6):897-908. doi: 10.1128/CVI.05726-11. Epub 2012 Apr 4.

30.

Replication-incompetent influenza A viruses that stably express a foreign gene.

Ozawa M, Victor ST, Taft AS, Yamada S, Li C, Hatta M, Das SC, Takashita E, Kakugawa S, Maher EA, Neumann G, Kawaoka Y.

J Gen Virol. 2011 Dec;92(Pt 12):2879-88. doi: 10.1099/vir.0.037648-0. Epub 2011 Aug 31.

31.

Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.

Nakauchi M, Ujike M, Obuchi M, Takashita E, Takayama I, Ejima M, Oba K, Konomi N, Odagiri T, Tashiro M, Kageyama T; influenza virus surveillance group of Japan.

J Med Virol. 2011 Jul;83(7):1121-7. doi: 10.1002/jmv.22101. Erratum in: J Med Virol. 2011 Aug;83(8):1491. multiple investigator names added.

PMID:
21567417
32.

Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.

Ujike M, Ejima M, Anraku A, Shimabukuro K, Obuchi M, Kishida N, Hong X, Takashita E, Fujisaki S, Yamashita K, Horikawa H, Kato Y, Oguchi A, Fujita N, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan.

Emerg Infect Dis. 2011 Mar;17(3):470-9. doi: 10.3201/eid1703.101188.

33.

Role of the CM2 protein in the influenza C virus replication cycle.

Furukawa T, Muraki Y, Noda T, Takashita E, Sho R, Sugawara K, Matsuzaki Y, Shimotai Y, Hongo S.

J Virol. 2011 Feb;85(3):1322-9. doi: 10.1128/JVI.01367-10. Epub 2010 Nov 24.

34.

Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy adults.

Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo S, Nishimura H, Matsuzaki Y.

J Med Virol. 2010 Dec;82(12):2092-6. doi: 10.1002/jmv.21920.

PMID:
20981798
35.

Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-September, 2009: temporal and spatial spreading profile of the viruses in Japan.

Shiino T, Okabe N, Yasui Y, Sunagawa T, Ujike M, Obuchi M, Kishida N, Xu H, Takashita E, Anraku A, Ito R, Doi T, Ejima M, Sugawara H, Horikawa H, Yamazaki S, Kato Y, Oguchi A, Fujita N, Odagiri T, Tashiro M, Watanabe H.

PLoS One. 2010 Jun 10;5(6):e11057. doi: 10.1371/journal.pone.0011057.

36.

Comparison of virus isolation using the Vero E6 cell line with real-time RT-PCR assay for the detection of human metapneumovirus.

Matsuzaki Y, Mizuta K, Takashita E, Okamoto M, Itagaki T, Katsushima F, Katsushima Y, Nagai Y, Nishimura H.

BMC Infect Dis. 2010 Jun 14;10:170. doi: 10.1186/1471-2334-10-170.

37.

A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.

Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh K, Sugawara K, Takashita E, Itagaki T, Katsushima Y, Ujike M, Obuchi M, Odagiri T, Tashiro M.

Virol J. 2010 Mar 5;7:53. doi: 10.1186/1743-422X-7-53.

38.

Influenza C virus NS1 protein upregulates the splicing of viral mRNAs.

Muraki Y, Furukawa T, Kohno Y, Matsuzaki Y, Takashita E, Sugawara K, Hongo S.

J Virol. 2010 Feb;84(4):1957-66. doi: 10.1128/JVI.01627-09. Epub 2009 Dec 9.

39.

Development and evaluation of a whole virus-based enzyme-linked immunosorbent assay for the detection of human metapneumovirus antibodies in human sera.

Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo S, Mizuta K, Itagaki T, Nishimura H, Matsuzaki Y.

J Virol Methods. 2010 Mar;164(1-2):24-9. doi: 10.1016/j.jviromet.2009.11.019. Epub 2009 Nov 17.

PMID:
19925829
40.

Evaluation of a new rapid antigen test using immunochromatography for detection of human metapneumovirus in comparison with real-time PCR assay.

Matsuzaki Y, Takashita E, Okamoto M, Mizuta K, Itagaki T, Katsushima F, Katsushima Y, Nagai Y, Nishimura H.

J Clin Microbiol. 2009 Sep;47(9):2981-4. doi: 10.1128/JCM.00321-09. Epub 2009 Jul 1.

41.

Intracellular localization of influenza C virus NS2 protein (NEP) in infected cells and its incorporation into virions.

Kohno Y, Muraki Y, Matsuzaki Y, Takashita E, Sugawara K, Hongo S.

Arch Virol. 2009;154(2):235-43. doi: 10.1007/s00705-008-0292-6. Epub 2009 Jan 8.

PMID:
19130168
42.

A mutation on influenza C virus M1 protein affects virion morphology by altering the membrane affinity of the protein.

Muraki Y, Murata T, Takashita E, Matsuzaki Y, Sugawara K, Hongo S.

J Virol. 2007 Aug;81(16):8766-73. Epub 2007 May 30.

43.

A nationwide epidemic of influenza C virus infection in Japan in 2004.

Matsuzaki Y, Abiko C, Mizuta K, Sugawara K, Takashita E, Muraki Y, Suzuki H, Mikawa M, Shimada S, Sato K, Kuzuya M, Takao S, Wakatsuki K, Itagaki T, Hongo S, Nishimura H.

J Clin Microbiol. 2007 Mar;45(3):783-8. Epub 2007 Jan 10.

44.

Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy.

Kawaguchi K, Inamura H, Abe Y, Koshu H, Takashita E, Muraki Y, Matsuzaki Y, Nishimura H, Ishikawa H, Fukao A, Hongo S, Aoyagi M.

Laryngoscope. 2007 Jan;117(1):147-56.

PMID:
17202945
45.

The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease.

Arawaka S, Wada M, Goto S, Karube H, Sakamoto M, Ren CH, Koyama S, Nagasawa H, Kimura H, Kawanami T, Kurita K, Tajima K, Daimon M, Baba M, Kido T, Saino S, Goto K, Asao H, Kitanaka C, Takashita E, Hongo S, Nakamura T, Kayama T, Suzuki Y, Kobayashi K, Katagiri T, Kurokawa K, Kurimura M, Toyoshima I, Niizato K, Tsuchiya K, Iwatsubo T, Muramatsu M, Matsumine H, Kato T.

J Neurosci. 2006 Sep 6;26(36):9227-38.

46.

Conformational maturation of the nucleoprotein synthesized in influenza C virus-infected cells.

Sugawara K, Muraki Y, Takashita E, Matsuzaki Y, Hongo S.

Virus Res. 2006 Dec;122(1-2):45-52. Epub 2006 Jul 25.

PMID:
16870298
47.

Isolation of an influenza C virus introduced into Japan by a traveler from Malaysia.

Matsuzaki Y, Sato K, Sugawara K, Takashita E, Muraki Y, Morishita T, Kumagai N, Suzuki S, Hongo S.

J Clin Microbiol. 2005 Feb;43(2):993-5.

48.

Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin.

Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S.

J Virol. 2004 Sep;78(18):9605-11.

49.

Characterization of antigenically and genetically similar influenza C viruses isolated in Japan during the 1999-2000 season.

Matsuzaki Y, Takao S, Shimada S, Mizuta K, Sugawara K, Takashita E, Muraki Y, Hongo S, Nishimura H.

Epidemiol Infect. 2004 Aug;132(4):709-20.

50.

Genetic diversity of influenza B virus: the frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community.

Matsuzaki Y, Sugawara K, Takashita E, Muraki Y, Hongo S, Katsushima N, Mizuta K, Nishimura H.

J Med Virol. 2004 Sep;74(1):132-40.

PMID:
15258979

Supplemental Content

Loading ...
Support Center